Eldecalcitol for the treatment of osteoporosis

Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new ana...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Noguchi Y, Kawate H, Nomura M, Takayanagi R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	vitamin D osteoporosis bone mineral density nonvertebral fracture Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/d92455598d83403db30783a389f5ae1e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d92455598d83403db30783a389f5ae1e
record_format	dspace
spelling	oai:doaj.org-article:d92455598d83403db30783a389f5ae1e2021-12-02T00:12:09ZEldecalcitol for the treatment of osteoporosis1178-1998https://doaj.org/article/d92455598d83403db30783a389f5ae1e2013-09-01T00:00:00Zhttps://www.dovepress.com/eldecalcitol-for-the-treatment-of-osteoporosis-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (>11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.Keywords: vitamin D, osteoporosis, bone mineral density, nonvertebral fractureNoguchi YKawate HNomura MTakayanagi RDove Medical Pressarticlevitamin Dosteoporosisbone mineral densitynonvertebral fractureGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 1313-1321 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	vitamin D osteoporosis bone mineral density nonvertebral fracture Geriatrics RC952-954.6
spellingShingle	vitamin D osteoporosis bone mineral density nonvertebral fracture Geriatrics RC952-954.6 Noguchi Y Kawate H Nomura M Takayanagi R Eldecalcitol for the treatment of osteoporosis
description	Yuko Noguchi, Hisaya Kawate, Masatoshi Nomura, Ryoichi TakayanagiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Eldecalcitol (1α, 25-dihydroxy-2β-[3-hydroxypropyloxy] vitamin D3; ED-71) is a new analog of the active form of vitamin D. Eldecalcitol has recently been approved for the treatment of osteoporosis in Japan. In addition to regulation of calcium metabolism carried out by conventional vitamin D analogs, eldecalcitol possesses a strong inhibitory effect on bone resorption and causes a significant increase in bone mineral density. A Phase III clinical trial on osteoporosis showed that eldecalcitol reduced the incidence of new vertebral fractures over 3 years by 26% compared with alfacalcidol. Although the overall risk of nonvertebral fractures was not reduced by eldecalcitol, the risk of wrist fracture was decreased significantly in the eldecalcitol group (71%) compared with the alfacalcidol group. The serum level of 25-hydroxyvitamin D (25[OH]D) was normalized by supplementation of native vitamin D in this trial, so the desirable effects on bone by eldecalcitol were considered to be derived from its distinctive pharmacological action. Increased blood calcium was observed in 21% of patients treated with eldecalcitol, and hypercalcemia (>11.5 mg/dL) occurred in 0.4% of eldecalcitol recipients, so serum calcium concentration should be monitored after starting eldecalcitol treatment. Eldecalcitol has dual effects on the metabolism of bone and calcium and is useful for the treatment of osteoporosis, especially for elderly patients (who frequently suffer from vitamin D deficiency). This article reviews the clinical efficacy and safety of eldecalcitol in the treatment of osteoporosis.Keywords: vitamin D, osteoporosis, bone mineral density, nonvertebral fracture
format	article
author	Noguchi Y Kawate H Nomura M Takayanagi R
author_facet	Noguchi Y Kawate H Nomura M Takayanagi R
author_sort	Noguchi Y
title	Eldecalcitol for the treatment of osteoporosis
title_short	Eldecalcitol for the treatment of osteoporosis
title_full	Eldecalcitol for the treatment of osteoporosis
title_fullStr	Eldecalcitol for the treatment of osteoporosis
title_full_unstemmed	Eldecalcitol for the treatment of osteoporosis
title_sort	eldecalcitol for the treatment of osteoporosis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/d92455598d83403db30783a389f5ae1e
work_keys_str_mv	AT noguchiy eldecalcitolforthetreatmentofosteoporosis AT kawateh eldecalcitolforthetreatmentofosteoporosis AT nomuram eldecalcitolforthetreatmentofosteoporosis AT takayanagir eldecalcitolforthetreatmentofosteoporosis
_version_	1718403894196830208

Eldecalcitol for the treatment of osteoporosis

Ejemplares similares